GO
Loading...

Pharmacyclics Inc

More

  • Feb 25- Cancer drug maker Pharmacyclics Inc is exploring a sale and has attracted interest from Johnson& Johnson and Novartis AG, Bloomberg reported. Pharmacyclics could fetch $17 billion- $18 billion from a possible sale, Bloomberg said on Wednesday, citing people familiar with the matter. A Pharmacyclics official said the company does not comment on rumors or...

  • Feb 25- Cancer drugmaker Pharmacyclics Inc is exploring a possible sale of the company and has attracted interest from Johnson& Johnson and Novartis AG, Bloomberg reported, citing people familiar the matter. Pharmacyclics could fetch $17- $18 billion from a possible sale, Bloomberg said on Wednesday. Sales of Imbruvica, which got U.S. Food& Drug Administration...

  • Nasdaq stocks posting largest percentage increases Wednesday, 25 Feb 2015 | 1:18 PM ET

    Benefitfocus Inc. rose 62.4 percent to $37.31. Oneida Financial Corp. rose 46.6 percent to $19.43. WaferGen Bio-systems Inc. rose 22.1 percent to $5.14.

  • Pharmacyclics misses 4Q profit forecasts Wednesday, 18 Feb 2015 | 4:18 PM ET

    SUNNYVALE, Calif. _ Pharmacyclics Inc. on Wednesday reported fourth-quarter earnings of $63.5 million. The average estimate of analysts surveyed by Zacks Investment Research was for earnings of 90 cents per share. Pharmacyclics shares have risen 39 percent since the beginning of the year.

  • Feb 17- Pharmacyclics Inc said its cancer drug developed with a Johnson& Johnson unit improved overall response rate in high-risk leukemia patients. About 115,000 patients suffer from CLL in the United States and about 16,000 are newly diagnosed each year. Shares of Pharmacyclics were up 1.4 percent at $165.69 in early trading on the Nasdaq.

  • The regulator's decision, which comes in over two months ahead of its review date, represents a fourth indication for the drug, sold by Johnson& Johnson and Pharmacyclics Inc. Although WM occurs only in up to 1,500 patients in the United States each year, the approval highlights the strength of the Imbruvica franchise, Roth Capital Partner's Joseph Pantginis...

  • FDA expands use of Imbruvica to treat rare form of cancer Thursday, 29 Jan 2015 | 11:29 AM ET

    Jan 29- The U.S. Food and Drug Administration said it cleared an expanded use of Imbruvica to treat Waldenström's macroglobulinemia, a rare form of cancer that begins in the body's immune system. The approval represents a fourth indication for the drug, sold by Johnson& Johnson and Pharmacyclics Inc, since its initial approval in November 2013.

  • Nov 20- Global pharmaceutical spending will break the trillion dollar mark in 2014, driven by high prices in the United States for novel treatments such as Gilead Sciences Inc's Sovaldi for hepatitis C and new cancer drugs, according to a study released on Thursday. Total spending on drugs will hit $1.06 trillion, an increase of 7 percent over 2013 levels,...

  • Midday Movers: Blackberry, Corning, Windstream & More Tuesday, 29 Jul 2014 | 12:48 PM ET

    Some of Tuesday's midday movers:

  • Gilead beat Street estimates as Sovaldi sales soar Wednesday, 23 Jul 2014 | 4:05 PM ET

    Gilead Sciences delivered quarterly earnings and revenue that topped analysts' expectations on Wednesday.

  • Midday movers: Allergan, Valeant, US Steel & more Monday, 2 Jun 2014 | 12:20 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Take a look at some of Monday's midday movers:

  • Why these 3 biotech stocks are making big moves Monday, 2 Jun 2014 | 9:44 AM ET

    Thousands of oncologists, investors, researchers and analysts descended on Chicago for the annual ASCO, the year's biggest cancer research meeting.

  • Lightning Round: Valero, Plug Power & More Monday, 5 May 2014 | 6:48 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Midday movers: Chevron, Skechers & More Friday, 2 May 2014 | 12:29 PM ET

    Friday's midday movers:

  • Lightning Round: Southwest Airlines, Blackstone & More Wednesday, 16 Apr 2014 | 6:47 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • J&J beats forecasts, helped by new medicines Tuesday, 15 Apr 2014 | 10:06 AM ET

    Johnson & Johnson turned in a solid first quarter Tuesday, topping analysts' profit and revenue estimates and increasing its 2014 earnings forecast by 5 cents a share.

  • Midday movers: Herbalife, Eli Lilly, Cray & More Tuesday, 7 Jan 2014 | 12:49 PM ET

    Some of Tuesday's midday movers:

  • Early movers: AAL, TWC, DIS, AAPL & more Monday, 9 Dec 2013 | 7:35 AM ET

    Some of the names on the move ahead of the open.

  • Lightning Round: Apple, Arena Pharma & More Monday, 11 Nov 2013 | 6:42 PM ET

    It’s time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Lightning round: Wolverine World Wide and more Monday, 4 Nov 2013 | 6:59 PM ET

    "Mad Money" host Jim Cramer made calls on stocks viewers asked about.